Gsa Capital Partners LLP Atara Biotherapeutics, Inc. Transaction History

Gsa Capital Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 16, 2024	BUY	$0.23 - $1.74 $180,404 - $1.36 Million	784,367 New	784,367 $400,000
Q1 2023 May 12, 2023	BUY	$2.8 - $5.46 $148,184 - $288,959	52,923 Added 300.78%	70,518 $204,000
Q4 2022 Feb 13, 2023	SELL	$2.85 - $5.18 $107,197 - $194,835	-37,613 Reduced 68.13%	17,595 $58,000
Q3 2022 Nov 14, 2022	BUY	$2.85 - $8.73 $157,342 - $481,965	55,208 New	55,208 $209,000
Q2 2022 Aug 09, 2022	SELL	$4.69 - $9.84 $67,845 - $142,345	-14,466 Closed	0 $0

Q1 2022 May 11, 2022	SELL	$8.44 - $16.89 $83,682 - $167,464	-9,915 Reduced 40.67%	14,466 $134,000
Q4 2021 Feb 14, 2022	BUY	$14.7 - $19.89 $358,400 - $484,938	24,381 New	24,381 $384,000
Q2 2021 Aug 05, 2021	SELL	$12.89 - $16.58 $167,582 - $215,556	-13,001 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$14.0 - $20.72 $182,014 - $269,380	13,001 New	13,001 $187,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.